|
業務類別
|
Biotechnology |
|
業務概覽
|
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue. |
| 公司地址
| 2929 7th Street, Suite 105, Berkeley, CA, USA, 94710 |
| 電話號碼
| +1 510 982-6030 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.cariboubio.com |
| 員工數量
| 97 |
| Dr. Rachel Haurwitz, PhD |
President, Chief Executive Officer and Director |
美元 667.53K |
24/04/2026 |
| Mr. Sriram Ryali, M.B.A. |
Chief Financial Officer and Principal Accounting Officer |
美元 483.16K |
24/04/2026 |
| Mr. Tim Kelly, M.B.A. |
Chief Technology Officer |
-- |
24/04/2026 |
| Dr. Tina Albertson, M.D.,PhD |
Chief Medical Officer |
-- |
24/04/2026 |
| Ms. Barbara G. McClung, J.D. |
Chief Legal Officer and Corporate Secretary |
美元 502.03K |
24/04/2026 |
| Ms. Ruhi Ahmad Khan, M.B.A. |
Chief Business Officer |
-- |
24/04/2026 |
|
|
| Mr. Andrew L. Guggenhime, M.B.A. |
Chairman of the Board |
24/04/2026 |
| Mr. David L. Johnson, M.D. |
Independent Director |
24/04/2026 |
| Dr. Scott Braunstein, M.D. |
Independent Director |
24/04/2026 |
| Dr. Rachel Haurwitz, PhD |
President, Chief Executive Officer and Director |
24/04/2026 |
| Dr. Natalie Sacks, M.D. |
Independent Director |
24/04/2026 |
| Dr. Nancy C. Whiting, Pharm.D. |
Independent Director |
24/04/2026 |
| Ms. Ran Zheng, M.S. |
Independent Director |
24/04/2026 |
| Dr. Dara Richardson-Heron |
Independent Director |
24/04/2026 |
|
|
|
|
